Mar 20, 2009 - Flamel Technologies announced today that it has earned an additional $4 million milestone from GlaxoSmithKline pursuant to its Micropump license agreement for Coreg CR (carvedilol phosphate extended release capsules).
The details can be read here.
No comments:
Post a Comment